20 NOVEMBER 2026

NORTHERN 2 VCT PLC

DIVIDEND DECLARATION

Northern 2 VCT PLC (“the Company”) is pleased to declare an interim dividend of 1.7 pence per ordinary share in respect of the year ending 31 March 2027. The interim dividend will be paid on 20 January 2027 to shareholders on the register on 18 December 2026. The ex-dividend date is 17 December 2026.

The Company’s dividend investment scheme, which enables shareholders to invest their dividends in new ordinary shares free of dealing costs and with the benefit of the tax reliefs available on new VCT share subscriptions, continues to operate. Details on how to join the scheme are included within the dividend section of our website, which can be found here: www.mercia.co.uk/vcts/n2vct/

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

20 NOVEMBER 2026

NORTHERN 3 VCT PLC

DIVIDEND DECLARATION

Northern 3 VCT PLC (“the Company”) is pleased to declare an interim dividend of 2.0 pence per ordinary share in respect of the year ending 31 March 2027. The interim dividend will be paid on 20 January 2027 to shareholders on the register on 18 December 2026. The ex-dividend date is 17 December 2026.

The Company’s dividend investment scheme, which enables shareholders to invest their dividends in new ordinary shares free of dealing costs and with the benefit of the tax reliefs available on new VCT share subscriptions, continues to operate. Details on how to join the scheme are included within the dividend section of our website, which can be found here: www.mercia.co.uk/vcts/n3vct/

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

UAB Urbo bankas, juridinio asmens kodas 112027077, adresas: Konstitucijos pr. 18B, Vilnius. 

THIS NOTICE IS NOT INTENDED, EXPRESSLY OR BY IMPLICATION, IN WHOLE OR IN PART, FOR DISTRIBUTION OR DISSEMINATION IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION, AND MAY NOT BE TRANSFERRED TO ANY JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION OF THIS NOTICE WOULD BE UNLAWFUL. CERTAIN OTHER RESTRICTIONS APPLY. PLEASE READ THE IMPORTANT DISCLAIMER BELOW IN THIS NOTICE TO THE SECURITY EXCHANGE.

Urbo bankas, UAB (also the Company) has prepared the base prospectus (the Prospectus) for a programme of fixed-rate Tier 2 subordinated bonds (ISIN LT0000139594) with a nominal value of up to EUR 15,000,000 and a maturity of up to 10 years (the Bonds), which has been approved by the Bank of Lithuania on 20 November 2026.

Meetings with investors in Lithuania, Latvia and Estonia are planned in the near future. Artea bankas, AB has been selected as sole arranger and distributor of the issue.

IMPORTANT NOTICE:

Legislation in certain jurisdictions may restrict the right to distribute this announcement and other information relating to securities. Persons who receive this announcement or other relevant information must familiarise themselves with and comply with such restrictions. This announcement is not intended for distribution to news agencies in the United States or for dissemination in the United States or in any other jurisdiction where such dissemination is not permitted. Furthermore, the securities referred to in this notice have not been and will not be registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States or to persons in the United States, unless such securities are registered under the Securities Act or an exemption from the registration requirements of the Securities Act is obtained. No public offering of securities will be made in the United States of America.

This notice does not constitute an offer or a solicitation to sell or to purchase securities or investments in any jurisdiction where such an offer or solicitation would be unlawful. The Prospectus is the only legally binding document containing information about the Company, the Bonds and their admission to trading on a regulated market. The Prospectus is published on the Company’s website at https://urbo.lt/lt, as well as at www.nasdaqbaltic.com.

The approval of the Prospectus should not be regarded as an endorsement of the quality of the Bonds to be admitted to trading on a regulated market. Prospective investors are advised to read the Prospectus before making an investment decision so that they understand all the potential risks and returns associated with the decision to invest in the Bonds.

Person responsible for the publication of information:

Julius Ivaška
Head of Business Division of UAB Urbo bankas
Phone: +370 601 04 453
e-mail: media@urbo.lt

Attachments

20 November 2026

Northern 3 VCT PLC
Half-Yearly Financial Report for the six months ended 30 September 2026

Northern 3 VCT PLC is a Venture Capital Trust (VCT) managed by Mercia Fund Management Limited. It invests mainly in unquoted venture capital holdings and aims to provide long-term tax-free returns to shareholders through a combination of dividend yield and capital growth.

Financial summary

  Unaudited six months ended
30 September
2026
Unaudited six months ended
30 September
2025
Audited year
ended
31 March
2026
Net assets £151.0m £131.8m £134.2m
Net asset value per share 85.9p 89.2p 85.1p
Return per share      
Revenue 0.2p 0.2p 0.4p
Capital 2.8p 1.4p (1.0)p
Total 3.0p 1.6p (0.6)p
Dividend per share declared in respect of the period 2.0p 2.0p 4.5p
Cumulative return to shareholders since launch      
Net asset value per share 85.9p 89.2p 85.1p
Dividends paid per share* 129.1p 124.6p 126.6p
Net asset value plus dividends paid per share 215.0p 213.8p 211.7p
Mid-market share price at end of period 82.0p 84.0p 83.5p
Share price discount to net asset value 4.5% 5.8% 1.9%
Tax-free dividend yield
(based on net asset value per share)**
5.0% 5.1% 5.0%

* Excluding interim dividend not yet paid.

** The dividend yield is calculated by dividing the dividends declared in the 12-month period ended on each reference date by the net asset value per share at the start of that period.

Half-yearly financial report

Results and dividend
The unaudited net asset value (NAV) per share at 30 September 2026 was 85.9 pence (85.1 pence (audited) on 31 March 2026), after deducting the final dividend for the year to 31 March 2026 of 2.5 pence paid in September 2026. The total return per share before dividends for the six months ended 30 September 2026 as shown in the income statement was 3.0 pence, compared with 1.6 pence in the corresponding period last year, equivalent to 3.5% of the opening NAV per share.

It remains our objective to pay a dividend at least equivalent to 4.5% of the opening NAV in each year. The Board has declared an interim dividend for the year ending 31 March 2027 of 2.0 pence per share, which will be paid on 20 January 2027 to shareholders who are on the register on 18 December 2026.

Venture capital investment activity and portfolio update
The value of the portfolio increased by £5.8 million, made up of unrealised gains of £0.6 million and realised gains of £5.2 million over the 31 March 2026 holding value. Good performances from a number of our holdings more than offset reductions in the valuations of companies that have performed less well. Pure Pet Food increased in value by £2.5 million (including the partial realisation), Risk Ledger by £0.7 million and Semble by £0.6 million, while the largest reductions were in Scalpel and Axis Spine Technologies.

We sold our remaining holding in The Beauty Tech Group for £7.2 million. Together with the £2.3 million realised at its Initial Public Offering on the London Stock Exchange in October 2025, this investment delivered a 7.4x return on our original investment cost. The Northern VCTs have supported the company since 2018. In July 2026, Send Technology Solutions was sold for initial proceeds of £3.5 million, an initial 1.7x return on investment cost. Our holding in Buoyant Upholstery was sold for an initial £1.0 million, a lifetime return of 2.5x. We also realised part of our holding in Pure Pet Food for £1.3 million, 5.5x the cost of the shares sold. Our remaining AIM-quoted holdings in Netcall, Pebble Beach Systems, ECO Animal Health, Synectics, CelLBxHealth and Velocity Composites were sold during the period for total proceeds of £1.2 million. In aggregate, realisations in the period were £5.2 million above the total 31 March 2026 holding values.

During the six months, we made five new investments totalling £4.7 million: Flok Health (£1.0 million), a digital healthcare company providing AI-enabled physiotherapy services; Fifth Dimension AI (£1.0 million), a software company providing decision-intelligence tools for the real estate and real-assets sector; PlannerPal (£1.0 million), a provider of financial adviser workflow and compliance software; Equals (£0.9 million), a music-focused social networking and engagement platform; and Givestar (£0.8 million), a digital fundraising and charitable giving platform. We also invested £2.8 million in seven companies in our portfolio. Since the period end we have made a second tranche investment in Givestar of £1.5 million and an investment of £1.5 million in Bureau, a provider of office booths and meeting pods. We have also invested £0.8 million in five existing portfolio companies.

Shareholder issues
As a result of the extension of the 2025/26 share offer, 20,180,102 shares were issued on 2 April 2026 for gross proceeds of £18.2 million. In order to continue to support our existing portfolio and invest in new early-stage opportunities, we are currently fundraising in conjunction with the other Northern VCTs. Full details of how to participate are available on the Company’s website at www.mercia.co.uk/vcts.

We have maintained our policy of being willing to buy back the Company’s shares in the market to maintain liquidity, at a 5% discount to NAV. During the period a total of 2,490,400 shares were purchased by the Company for cancellation, representing around 1.6% of the opening ordinary share capital.

During the period the Company cancelled its share premium account, transferring £95.8 million to the capital reserve and increasing the reserves available for distribution, share buy-backs and the payment of expenses.

We continue to operate our dividend investment scheme, which enables shareholders to invest their dividends in new ordinary shares free of dealing costs and with the benefit of the tax reliefs available on new VCT share subscriptions. In September 2026, 521,852 new shares were issued under the scheme in respect of the final dividend. Details of the scheme can be found within the dividend section of our website at www.mercia.co.uk/vcts/n3vct/.

Board composition
Chris Fleetwood and Tim Levett retired from the Board at the Annual General Meeting on 30 July 2026, having served since the Company’s incorporation. On behalf of the shareholders, we are grateful to them for their outstanding contributions to the Company. Jamie Younger, who joined the Board on 13 February 2026, has succeeded Chris as Chair of the Audit & Risk Committee.

Management fee
With effect from 1 October 2026, the Board has agreed revised fee arrangements with Mercia. The annual management fee has reduced from 2.06% to 2.00% of net assets, while the fee on cash balances has been restructured to reflect the level of cash held for future investment. Mercia will also no longer charge initial management fees to new portfolio companies. The Board believes this will benefit shareholders by making the Company a more attractive investor to high-quality, early-stage businesses, improving our access to the best opportunities and ensuring more of the capital we invest goes directly into growing those businesses. Further details are set out at the end of this announcement.

VCT legislation and qualifying status
The Company has continued to meet the stringent and complex qualifying conditions laid down by HM Revenue & Customs for maintaining its approval as a VCT. The Investment Manager monitors the position closely and reports regularly to the Board. Philip Hare & Associates LLP has continued to act as independent adviser to the Company on VCT taxation matters.

As reported in the Annual Report, with effect from 6 April 2026, the annual and lifetime investment limits for VCT-qualifying companies were increased and income tax relief on new VCT subscriptions was reduced from 30% to 20%. The impact on investor appetite for VCTs remains uncertain, but the Company is well capitalised and intends to continue fundraising, investment and its other activities as usual.

Outlook
We remain confident in the resilience and long-term growth potential of the portfolio, despite ongoing geopolitical and economic uncertainties. With a strong cash position, we will continue to invest selectively, supporting businesses with strong fundamentals and the potential for high growth, while also seeking to make realisations where opportunities arise.

On behalf of the Board

James Ferguson
Chairman

Statement of the Directors’ responsibilities

Responsibility statement
In accordance with Disclosure and Transparency Rule (DTR) 4.2.10, James Ferguson (Chairman), Jamie Younger (Chair of the Audit & Risk Committee), Anna Brown, David Ovens and John Waddell, being the Directors of the Company, confirm that to the best of their knowledge:

(a) the condensed set of financial statements, which has been prepared in accordance with Financial Reporting Standard 104 “Interim Financial Reporting”, gives a true and fair view of the assets, liabilities, financial position and profit of the Company as required by DTR 4.2.10;

(b) the Half-Yearly Financial Report includes a fair review of the information required by DTR 4.2.7, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;

(c) a description of the principal risks and uncertainties facing the Company for the remaining six months of the financial year is set out under the summary of principal risks and uncertainties below, in accordance with DTR 4.2.7; and

(d) other than the change in the management fee referred to in the Chairman’s statement, there were no related party transactions in the first six months of the current financial year that are required to be disclosed, in accordance with DTR 4.2.8.

Principal risks and uncertainties
In accordance with DTR 4.2.7, the Board confirms that the principal risks and uncertainties facing the Company have not materially changed from those identified in the Annual Report and Financial Statements for the year ended 31 March 2026 (“the Annual Report”). The Board considers that the present processes for mitigating those risks remain appropriate. Following the realisation of all the Company’s quoted investments, the Board has removed stock market risk from the principal risks.

The principal risks faced by the Company are:

  • Artificial intelligence and advanced technology risk
  • Availability of qualifying investments risk
  • Economic and geopolitical risk
  • Financial risk
  • Investment and liquidity risk
  • Legislative and regulatory risk
  • Operational risk
  • Performance of the Investment Manager risk
  • VCT qualifying status risk

A detailed explanation of the principal risks facing the Company can be found in the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 28 to 30, as well as in Note 18 on Financial Instruments on pages 80 to 83 of that report. Copies can be viewed or downloaded from the Company’s website: www.mercia.co.uk/vcts.

Environmental, Social and Governance considerations
The Company is committed to conducting its affairs responsibly and considers environmental, social and governance (ESG) issues as part of its operations. More details of the Company’s considerations can be found in the Responsible Investment section in the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 31 to 33.

Going concern
The Board has assessed the Company’s operation as a going concern. The Company’s business activities, together with the factors likely to affect its future development, performance and position are set out earlier in the Half-Yearly Financial Report. The Directors have satisfied themselves that the Company’s cash position is adequate to enable the Company to continue as a going concern under downside scenarios. The portfolio remains well funded and the Manager’s investment team are ensuring that management teams undertake adequate cost control and cash flow planning. The major cash outflows of the Company (namely investments, share buy-backs and dividends) are within the Company’s control. The Board’s assessment of liquidity risk and details of the Company’s policies for managing its capital and financial risks are shown in Note 18 of the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 80 to 83. Accordingly, the Directors continue to adopt the going concern basis of accounting in preparing the Half-Yearly Financial Report and financial statements.

Cautionary statement
This report may contain forward-looking statements with regard to the financial condition and results of the Company, which are made in the light of current economic and business circumstances. Nothing in this report should be construed as a profit forecast.

For and on behalf of the Board:

James Ferguson
Chairman
20 November 2026

Investment portfolio
As at 30 September 2026 (unaudited)

  Description Cost
£000
Valuation
£000
% of net assets
by value
Fifteen largest venture capital investments        
Pure Pet Food Production of organic pet food 1,278 7,967 5.3
Risk Ledger Cyber security focused on supply chain risk 3,073 5,254 3.5
Semble Practice management software for healthcare clinics 3,227 4,932 3.3
Pimberly Product information management software 1,910 3,226 2.1
Broker Insights Platform connecting insurers and brokers 3,164 3,164 2.1
Turbine Simulated Cell Technologies Simulation of cell reaction to disease treatment 2,552 2,731 1.8
Tutora (t/a Tutorful) Platform for parents/students to engage tutors 2,973 2,646 1.8
Biological Preparations Group Environmental biotechnology products 1,915 2,562 1.7
Forensic Analytics Call data communications analytics software 2,519 2,519 1.7
VoxPopMe Video-based consumer analysis platform 1,752 2,419 1.6
Rockar E-commerce and fulfilment platform for new car sales 1,660 2,410 1.6
Ski Zoom (t/a Heidi Ski) Booking platform for flexible winter mountain breaks 1,995 2,410 1.6
Centuro Global Platform to enable international expansion 2,066 2,341 1.6
Ridge Pharma Sale of pharmaceuticals (branded, generics, specials) 1,345 2,326 1.5
Thanks Ben Employee benefits orchestration platform 2,293 2,293 1.5
Fifteen largest venture capital investments   33,722 49,200 32.6
Other venture capital investments   57,956 48,242 31.9
Total venture capital investments   91,678 97,442 64.5
Net current assets     53,576 35.5
Net assets     151,018 100.0

Extracts from the unaudited half-yearly financial statements for the six months ended 30 September 2026 are set out below

Condensed income statement

For the six months ended 30 September 2026

  Unaudited six months ended Unaudited six months ended Audited year ended
  30 September 2026 30 September 2025 31 March 2026
  Revenue Capital Total Revenue Capital Total Revenue Capital Total
  £000 £000 £000 £000 £000 £000 £000 £000 £000
Gain/(loss) on disposal of investments – 5,190 5,190 – 294 294 – 304 304
Movements in fair value of investments – 586 586 – 2,703 2,703 – 6 6
                   
  – 5,776 5,776 – 2,997 2,997 – 310 310
                   
Dividend and interest income 1,061 – 1,061 993 – 993 1,853 – 1,853
Investment management fee (326) (977) (1,303) (313) (937) (1,250) (634) (1,903) (2,537)
Other expenses (280) – (280) (287) – (287) (578) – (578)
                   
Return before tax 455 4,799 5,254 393 2,060 2,453 641 (1,593) (952)
Tax on return (112) 112 – (35) 35 – (96) 96 –
                   
Return after tax 343 4,911 5,254 358 2,095 2,453 545 (1,497) (952)
                   
Return per share 0.2p 2.8p 3.0p 0.2p 1.4p 1.6p 0.4p (1.0)p (0.6)p

Condensed balance sheet

As at 30 September 2026

  Unaudited 30 September
2026
Unaudited 30 September
2025
Audited 31 March
2026
  £000 £000 £000
Fixed assets      
Investments 97,442 98,821 99,345
       
Current assets      
Debtors 953 124 174
Cash and cash equivalents 52,767 33,013 34,858
  53,720 33,137 35,032
       
Creditors (amounts falling due within one year) (144) (181) (196)
       
Net current assets 53,576 32,956 34,836
       
Net assets 151,018 131,777 134,181
       
Capital and reserves      
Called-up equity share capital 8,793 7,387 7,882
Share premium 434 68,128 79,198
Capital redemption reserve 1,671 1,384 1,547
Revaluation reserve 5,764 9,070 9,838
Capital reserve 133,350 44,644 34,524
Revenue reserve 1,006 1,164 1,192
Total equity shareholders’ funds 151,018 131,777 134,181
       
Net asset value per share 85.9p 89.2p 85.1p

Condensed statement of changes in equity

       
  Called-up share capital Share premium Capital redemption reserve Revaluation reserve Capital reserve Revenue reserve Total
  £000 £000 £000 £000 £000 £000 £000
Six months ended 30 September 2026 (unaudited)              
               
At 1 April 2026 7,882 79,198 1,547 9,838 34,524 1,192 134,181
Return after tax – – – (4,074) 8,985 343 5,254
Dividends paid – – – – (3,883) (529) (4,412)
Net proceeds of share issues 1,035 17,029 – – – – 18,064
Shares purchased for cancellation (124) – 124 – (2,033) – (2,033)
Cancellation of share premium account – (95,793) – – 95,793 – –
Costs of share premium cancellation – – – – (36) – (36)
At 30 September 2026 8,793 434 1,671 5,764 133,350 1,006 151,018
               
Six months ended 30 September 2025 (unaudited)      
At 1 April 2025 7,226 62,268 1,192 7,632 50,538 1,253 130,109
Return after tax – – – 1,438 657 358 2,453
Dividends paid – – – – (3,276) (447) (3,723)
Net proceeds of share issues 353 5,860 – – – – 6,213
Shares purchased for cancellation (192) – 192 – (3,275) – (3,275)
At 30 September 2025 7,387 68,128 1,384 9,070 44,644 1,164 131,777
               
Year ended 31 March 2026      
At 1 April 2025 7,226 62,268 1,192 7,632 50,538 1,253 130,109
Return after tax – – – 2,206 (3,703) 545 (952)
Dividends paid – – – – (6,296) (606) (6,902)
Net proceeds of share issues 1,011 16,930 – – – – 17,941
Shares purchased for cancellation (355) – 355 – (6,015) – (6,015)
At 31 March 2026 7,882 79,198 1,547 9,838 34,524 1,192 134,181

Condensed statement of cash flows

For the six months ended 30 September 2026

  Unaudited six months ended Unaudited six months ended Audited year ended
  30 September 2026 30 September 2025 31 March 2026
  £000 £000 £000
Cash flows from operating activities      
Return before tax 5,254 2,453 (952)
Adjustments for:      
(Gain)/loss on disposal of investments (5,190) (294) (304)
Movements in fair value of investments (586) (2,703) (6)
(Increase)/decrease in debtors (50) 2,171 17
(Decrease)/increase in creditors (51) (98) (83)
Net cash (outflow)/inflow from operating activities (623) 1,529 (1,328)
Cash flows from investing activities      
Purchase of investments (7,447) (5,638) (16,025)
Proceeds on disposal of investments 14,396 13,045 22,325
Net cash inflow/(outflow) from investing activities 6,949 7,407 6,300
Cash flows from financing activities      
Issue of ordinary shares 18,672 6,396 18,545
Share issue expenses (608) (183) (604)
Purchase of ordinary shares for cancellation (2,033) (3,275) (6,015)
Costs of share premium cancellation (36) – –
Equity dividends paid (4,412) (3,723) (6,902)
Net cash inflow/(outflow) from financing activities 11,583 (785) 5,024
Net increase in cash and cash equivalents 17,909 8,151 9,996
Cash and cash equivalents at beginning of period 34,858 24,862 24,862
Cash and cash equivalents at end of period 52,767 33,013 34,858

Other matters

The Financial Statements are prepared in accordance with accounting policies consistent with Financial Reporting Standard 102 (“FRS 102”), Financial Reporting Standard 104 (“FRS 104”) – Interim Financial Reporting, with the Companies Act 2006 and the Statement of Recommended Practice, ‘Financial Statements of Investment Trust Companies and Venture Capital Trusts’ (“the SORP”) (updated in December 2025) issued by the Association of Investment Companies (“AIC”). These condensed financial statements comply with FRS 104, applying the recognition and measurement principles of FRS 102. The Financial Statements have been prepared on a going concern basis.

The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The most critical estimates and judgements relate to the determination of carrying value of investments at fair value through profit or loss (“FVTPL”) in accordance with FRS 102 sections 11 and 12. The Company values investments by following the International Private Equity and Venture Capital Valuation (“IPEV”) Guidelines as updated in 2025 and further detail on the valuation techniques used is outlined in the Annual Report and Financial Statements for the year ended 31 March 2026.

The accounting policies have been applied consistently throughout the period. Full details of principal accounting policies are disclosed in Note 1 on page 67 of the Annual Report and Financial Statements for the year ended 31 March 2026. The significant accounting estimates and judgements applied are consistent with those disclosed in the Annual Report for the year ended 31 March 2026.

Details of the agreement under which the investment management fee and performance-related fee are paid are given in the Directors’ Report on page 41 and in Note 3 on page 70 of the Annual Report and Financial Statements for the year ended 31 March 2026. The investment management fee for the six months ended 30 September 2026 has been calculated in accordance with these arrangements. As previously announced, revised fee arrangements under the investment management agreement became effective on 1 October 2026. Under the revised arrangements, the annual management fee has been reduced from 2.06% to 2.00% of net assets, with amendments also made to the basis of calculating management fees on cash balances (now 1.75% on balances over £30 million – previously 1.00% on balances over £20 million) and the frequency of fee calculations. In addition, no initial management fees will be charged to new portfolio companies from that date.

The interim dividend of 2.0 pence per share for the year ending 31 March 2027 will be paid on 20 January 2027 to shareholders on the register on 18 December 2026.

The calculation of the return per share is based on the return after tax for the six months ended 30 September 2026 and on 177,169,553 (30 September 2025: 149,765,566) ordinary shares, being the weighted average number of shares in issue during the period.

The calculation of net asset value per share is based on the net assets at 30 September 2026 divided by the 175,856,561 (30 September 2025: 147,737,417) ordinary shares in issue at that date.

The information set out in this announcement does not constitute the Company’s statutory accounts within the terms of section 434 of the Companies Act 2006 for the periods ended 30 September 2026 and 30 September 2025 and is unaudited. The financial information for the year ended 31 March 2026 does not constitute statutory accounts within the terms of section 434 of the Companies Act 2006 and is derived from the statutory accounts for that financial year, which have been delivered to the Registrar of Companies. The Auditor reported on those accounts; their report was unqualified and did not contain a statement under s498(2) or (3) of the Companies Act 2006.

The Half-Yearly Financial Report is being sent to shareholders and copies will be made available to the public at the registered office of the Company, the National Storage Mechanism and also electronically at www.mercia.co.uk/vcts.

In 2027 AS Pro Kapital Grupp will disclose its consolidated financial results on the following dates:

EVENT DUE DATE DUE WEEK
2026 Q4 and annual unaudited results 26.02.2027  8 (2027)
2026 annual audited results 15.04.2027 15 (2027)
2027 Q1 unaudited results 21.05.2027 20 (2027)
2027 Q2 unaudited results 13.08.2027 32 (2027)
2027 Q3 unaudited results 19.11.2027 46 (2027)

Ann-Kristin Kuusik
CFO
+372 614 4920
prokapital@prokapital.com

20 November 2026

Northern 2 VCT PLC
Half-Yearly Financial Report for the six months ended 30 September 2026

Northern 2 VCT PLC is a Venture Capital Trust (VCT) managed by Mercia Fund Management Limited (the Manager). It invests mainly in unquoted venture capital holdings and aims to provide long-term tax-free returns to shareholders through a combination of dividend yield and capital growth.

Financial summary

  Unaudited six months ended
30 September
2026
Unaudited six months ended
30 September
2025
Audited year
ended
31 March
2026
Net assets £147.6m £138.4m £137.8m
Net asset value per share 55.4p 57.7p 54.6p
Return per share      
Revenue 0.1p 0.2p 0.3p
Capital 1.8p 0.7p (0.9)p
Total 1.9p 0.9p (0.6)p
Dividend per share declared in respect of the period 1.7p 1.7p 3.0p
Cumulative return to shareholders since launch      
Net asset value per share 55.4p 57.7p 54.6p
Dividends paid per share* 146.3p 143.3p 145.0p
Net asset value plus dividends paid per share 201.7p 201.0p 199.6p
Mid-market share price at end of period 53.0p 54.5p 53.5p
Share price discount to net asset value 4.3% 5.5% 2.0%
Tax-free dividend yield
(based on net asset value per share)**
5.2% 5.1% 5.1%

* Excluding interim dividend not yet paid.

** The dividend yield is calculated by dividing the dividends declared in the 12-month period ended on each reference date by the net asset value per share at the start of that period.

Half-yearly financial report

I am pleased to present our interim financial report for the six months to 30 September 2026. UK economic conditions during the period remained challenging: the prolonged conflict in the Middle East pushed energy prices sharply higher, consumer price inflation rose to 3.5% in September, and gilt yields reached their highest level since 2007 amid concern over the public finances. This month saw the Bank of England increase the interest rate to 4%, the first increase in more than three years, and further increases are expected by the markets in the near term.

Against this backdrop, your Company has maintained its long-term strategy of investing in promising early-stage businesses, supporting its existing portfolio companies, and generating cash from realisations where circumstances permit.

Venture capital investment activity and portfolio update
It has been a strong period for realisations with £13.4 million of proceeds generated from disposals. We sold our remaining holding in The Beauty Tech Group for £7.3 million. Together with the £2.3 million realised at its IPO on the London Stock Exchange in October 2025, the investment has delivered a 7.4x return on our original investment cost. We first invested in the company in 2018 with follow-on funding to support product innovation and growth of the company. In accordance with the VCT rules, following the IPO, we sold our remaining interest in the company.

Send Technology Solutions was sold for initial proceeds of £3.5 million, a 1.7x return on investment cost. Our holding in Buoyant Upholstery was sold for initial proceeds of £1.2 million, which represents a lifetime return of 2.5x. We also realised part of our holding in Pure Pet Food for £1.3 million, representing 5.5x the cost of the shares sold. The Company sold its remaining AIM-quoted holdings in CelLBxHealth and Velocity Composites for total proceeds of £19,000 following a decision to exit all AIM-quoted holdings. In aggregate, realisations in the period were £4.9 million above the total 31 March 2026 holding values.

In the period, the value of the portfolio overall increased by £5.7 million, comprising unrealised gains of £0.8 million and realised gains of £4.9 million over the 31 March 2026 holding value. Strong performances from a number of portfolio companies more than offset some necessary reductions in the valuations of companies that have performed less well. Pure Pet Food increased in value by £2.5 million (including the partial realisation), Risk Ledger by £0.6 million and Semble by £0.6 million, while the largest reductions were in Scalpel and Axis Spine Technologies.

During the period, we made five new investments totalling £4.6 million: Flok Health (£1.0 million), a digital healthcare company providing AI-enabled physiotherapy services; Fifth Dimension AI (£1.0 million), a software company providing decision-intelligence tools for the real estate and real-assets sector; PlannerPal (£1.0 million), a provider of financial adviser workflow and compliance software; Equals (£0.8 million), a music-focused social networking and engagement platform; and Givestar (£0.8 million), a digital fundraising and charitable giving platform. We also deployed £2.7 million into seven existing portfolio companies.

Since the period end we have made a second tranche investment in Taptap Giving (t/a Givestar) of £1.5 million and an investment of £1.5 million in Bureau Spaces (t/a Bureau), a provider of office booths and meeting pods. We have also invested £0.8 million in five existing portfolio companies.

Results and dividend
The Company achieved a return of 1.9 pence per share in the period (2025: 0.9 pence per share), equivalent to 3.5% of the audited net asset value (NAV) per share on 31 March 2026. After deducting the final dividend for the year to 31 March 2026 of 1.3 pence, paid in September 2026, and taking account of the accretive effect of share issues above NAV and buy-backs below it, the NAV per share at 30 September 2026 was 55.4 pence.

It remains our objective to pay a dividend at least equivalent to 5% of the opening NAV in each year. The Board has declared an interim dividend for the year ending 31 March 2027 of 1.7 pence per share, which will be paid on 20 January 2027 to shareholders who are on the register on 18 December 2026.

We continue to operate our dividend investment scheme, which enables shareholders to invest their dividends in new ordinary shares free of dealing costs and with the benefit of the tax reliefs available on new VCT share subscriptions. In September 2026, 738,824 new shares were issued under the scheme in respect of the final dividend. Details of the scheme can be found within the dividend section of our website at www.mercia.co.uk/vcts/n2vct/.

Shareholder issues
As a result of the extension of the 2025/26 share offer, 17,238,349 shares were issued on 2 April 2026 for gross proceeds of £10.0 million.

In order to continue to support our existing portfolio and invest in new early-stage opportunities, we are currently fundraising in conjunction with the other Northern VCTs. Full details of how to participate are available on the Company’s website at www.mercia.co.uk/vcts.

We have maintained our policy of being willing to buy back the Company’s shares in the market to maintain liquidity, at a 5% discount to NAV. During the period a total of 3,536,077 shares were purchased by the Company for cancellation, representing around 1.4% of the opening ordinary share capital.

Following approval from shareholders at the 2025 AGM, the Company cancelled its share premium account, transferring £94.3 million to the capital reserve and increasing the reserves available for distribution, share buy-backs and the payment of expenses.

Manager and investment management fees
With effect from 1 October 2026, the Board has agreed revised fee arrangements with Mercia. The annual management fee has reduced from 2.06% to 2.00% of net assets, while the fee on cash balances has been restructured to reflect the level of cash held for future investment. Mercia will also no longer charge initial management fees to new portfolio companies. The Board believes this will benefit shareholders by making the Company a more attractive investor to high-quality, early-stage businesses, improving our access to the best opportunities and ensuring more of the capital we invest goes directly into growing those businesses. Further details are set out at the end of this announcement.

Board composition
Simon Devonshire resigned from the Board on 10 September 2026 due to ill health. The Board would like to thank Simon for his many years of dedicated service and significant contribution to the Company and wishes him well for the future.

In the Company’s Annual Report issued on 11 June 2026, the Board had already outlined its plans to recruit an additional non-executive director as part of ongoing succession planning. The Board has commenced this process and will update shareholders in due course. It is the intention of the Board to appoint at least one non-executive director as part of this process.

Upon re-election as non-executive director at the Company’s AGM on 29 July 2026, David Gravells assumed the role of Senior Independent Director. There were no other Board changes.

VCT legislation and qualifying status
The Company has continued to meet the stringent and complex qualifying conditions laid down by HM Revenue & Customs for maintaining its approval as a VCT. The Investment Manager monitors the position closely and reports regularly to the Board. Philip Hare & Associates LLP has continued to act as independent adviser to the Company on VCT taxation matters.

With effect from 6 April 2026, the annual and lifetime investment limits for VCT-qualifying companies were increased and income tax relief on new VCT subscriptions was reduced from 30% to 20%. The impact on investor appetite for VCTs remains uncertain; however, the Company’s investment strategy of investing in promising early-stage businesses remains unchanged.

Outlook
Despite the ongoing geopolitical and economic uncertainties, the realisations achieved in the period demonstrate the quality of the portfolio and its ability to deliver value for shareholders. The Company will continue to invest selectively in high-growth businesses with strong fundamentals and support our existing portfolio companies through to exit. We remain confident in the resilience and long-term growth potential of the portfolio.

The Board very much appreciates the continuing support of shareholders.

On behalf of the Board

Thomas Chambers
Chair

Statement of the Directors’ responsibilities

Responsibility statement
In accordance with Disclosure and Transparency Rule (DTR) 4.2.10, Thomas Chambers (Chair), Ranjan Ramparia (Chair of the Audit & Risk Committee) and David Gravells (Senior Independent Director), being the Directors of the Company, confirm that to the best of their knowledge:

(a) the condensed set of financial statements, which has been prepared in accordance with Financial Reporting Standard 104 “Interim Financial Reporting”, gives a true and fair view of the assets, liabilities, financial position and profit of the Company as required by DTR 4.2.10;

(b) the Half-Yearly Financial Report includes a fair review of the information required by DTR 4.2.7, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;

(c) a description of the principal risks and uncertainties facing the Company for the remaining six months of the financial year is set out under the summary of principal risks and uncertainties below, in accordance with DTR 4.2.7; and

(d) other than the change in the management fee referred to in the Chair’s statement, there were no related party transactions in the first six months of the current financial year that are required to be disclosed, in accordance with DTR 4.2.8.

Principal risks and uncertainties
In accordance with DTR 4.2.7, the Board confirms that the principal risks and uncertainties facing the Company have not materially changed from those identified in the Annual Report and Financial Statements for the year ended 31 March 2026 (“the Annual Report”). The Board considers that the present processes for mitigating those risks remain appropriate. Following the realisation of all the Company’s quoted investments, the Board has removed stock market risks from the principal risks.

The principal risks faced by the Company are:

  • Artificial intelligence and advanced technology risk
  • Availability of qualifying investments risk
  • Economic and geopolitical risk
  • Financial risk
  • Investment and liquidity risk
  • Legislative and regulatory risk
  • Operational risk
  • Performance of the Investment Manager risk
  • VCT qualifying status risk

A detailed explanation of the principal risks facing the Company can be found in the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 28 to 30, as well as in Note 18 on Financial Instruments on pages 77 to 80 of that report. Copies can be viewed or downloaded from the Company’s website: www.mercia.co.uk/vcts.

Environmental, Social and Governance considerations
The Company is committed to conducting its affairs responsibly and considers environmental, social and governance (ESG) issues as part of its operations. More details of the Company’s considerations can be found in the Responsible Investment section in the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 31 to 33.

Going concern
The Board has assessed the Company’s operation as a going concern. The Company’s business activities, together with the factors likely to affect its future development, performance and position are set out earlier in the Half-Yearly Financial Report. The Directors have satisfied themselves that the Company’s cash position is adequate to enable the Company to continue as a going concern under downside scenarios. The portfolio remains well funded and the Manager’s investment team are ensuring that management teams undertake adequate cost control and cash flow planning. The major cash outflows of the Company (namely investments, share buy-backs and dividends) are within the Company’s control. The Board’s assessment of liquidity risk and details of the Company’s policies for managing its capital and financial risks are shown in Note 18 of the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 77 to 80. Accordingly, the Directors continue to adopt the going concern basis of accounting in preparing the Half-Yearly Financial Report and financial statements.

Cautionary statement
This report may contain forward-looking statements with regard to the financial condition and results of the Company, which are made in the light of current economic and business circumstances. Nothing in this report should be construed as a profit forecast.

For and on behalf of the Board:

Thomas Chambers
Chair
20 November 2026

Investment portfolio
As at 30 September 2026 (unaudited)

  Description Cost
£000
Valuation
£000
% of net assets
by value
Fifteen largest venture capital investments        
Pure Pet Food Production of organic pet food 1,281 7,987 5.4
Risk Ledger Cyber security focused on supply chain risk 2,980 5,095 3.5
Semble Practice management software for healthcare clinics 3,145 4,806 3.3
Pimberly Product information management software 1,876 3,169 2.1
Broker Insights Platform connecting insurers and brokers 3,053 3,053 2.1
Biological Preparations Group Environmental biotechnology products 2,166 2,913 2.0
Tutora (t/a Tutorful) Platform for parents/students to engage tutors 3,023 2,690 1.8
Turbine Simulated Cell Technologies Simulation of cell reaction to disease treatment 2,488 2,662 1.8
Rockar E-commerce and fulfilment platform for new car sales 1,766 2,564 1.7
Forensic Analytics Call data communications analytics software 2,475 2,475 1.7
VoxPopMe Video-based consumer analysis platform 1,781 2,459 1.7
Ridge Pharma Sale of pharmaceuticals (branded, generics, specials) 1,387 2,399 1.6
Thanks Ben Employee benefits orchestration platform 2,392 2,392 1.6
Ski Zoom (t/a Heidi Ski) Booking platform for flexible winter mountain breaks 1,960 2,368 1.6
Centuro Global Platform to enable international expansion 2,016 2,284 1.5
Fifteen largest venture capital investments   33,789 49,316 33.4
Other venture capital investments   57,835 48,080 32.6
Total venture capital investments   91,624 97,396 66.0
Net current assets     50,199 34.0
Net assets     147,595 100.0

Extracts from the unaudited half-yearly financial statements for the six months ended 30 September 2026 are set out below

Condensed income statement

For the six months ended 30 September 2026

  Unaudited six months ended Unaudited six months ended Audited year ended
  30 September 2026 30 September 2025 31 March 2026
  Revenue Capital Total Revenue Capital Total Revenue Capital Total
  £000 £000 £000 £000 £000 £000 £000 £000 £000
Gain/(loss) on disposal of investments – 4,881 4,881 – (2) (2) – (531) (531)
Movements in fair value of investments – 861 861 – 2,491 2,491 – (61) (61)
                   
  – 5,742 5,742 – 2,489 2,489 – (592) (592)
                   
Dividend and interest income 985 – 985 1,145 – 1,145 2,153 – 2,153
Investment management fee (329) (987) (1,316) (306) (918) (1,224) (632) (1,895) (2,527)
Other expenses (292) – (292) (289) – (289) (570) – (570)
                   
Return before tax 364 4,755 5,119 550 1,571 2,121 951 (2,487) (1,536)
Tax on return (90) 90 – (116) 116 – (216) 216 –
                   
Return after tax 274 4,845 5,119 434 1,687 2,121 735 (2,271) (1,536)
                   
Return per share 0.1p 1.8p 1.9p 0.2p 0.7p 0.9p 0.3p (0.9)p (0.6)p

Condensed balance sheet

As at 30 September 2026

  Unaudited 30 September
2026
Unaudited 30 September
2025
Audited 31 March
2026
  £000 £000 £000
Fixed assets      
Investments 97,396 95,380 98,447
       
Current assets      
Debtors 1,034 159 241
Cash and cash equivalents 49,332 43,052 39,316
  50,366 43,211 39,557
       
Creditors (amounts falling due within one year) (167) (185) (207)
       
Net current assets 50,199 43,026 39,350
       
Net assets 147,595 138,406 137,797
       
Capital and reserves      
Called-up equity share capital 13,330 11,985 12,608
Share premium 384 76,195 85,546
Capital redemption reserve 2,230 1,788 2,053
Revaluation reserve 5,773 7,483 10,393
Capital reserve 125,782 40,379 26,574
Revenue reserve 96 576 623
Total equity shareholders’ funds 147,595 138,406 137,797
       
Net asset value per share 55.4p 57.7p 54.6p

Condensed statement of changes in equity

       
  Called-up share capital Share premium Capital redemption reserve Revaluation reserve Capital reserve Revenue reserve Total
  £000 £000 £000 £000 £000 £000 £000
Six months ended 30 September 2026 (unaudited)              
               
At 1 April 2026 12,608 85,546 2,053 10,393 26,574 623 137,797
Return after tax – – – (4,620) 9,465 274 5,119
Dividends paid – – – – (2,672) (801) (3,473)
Net proceeds of share issues 899 9,142 – – – – 10,041
Shares purchased for cancellation (177) – 177 – (1,853) – (1,853)
Cancellation of share premium account* – (94,304) – – 94,304 – –
Costs of share premium cancellation – – – – (36) – (36)
At 30 September 2026 13,330 384 2,230 5,773 125,782 96 147,595
               
Six months ended 30 September 2025 (unaudited)      
At 1 April 2025 10,993 62,633 1,468 4,939 47,177 868 128,078
Return after tax – – – 2,544 (857) 434 2,121
Dividends paid – – – – (2,419) (726) (3,145)
Net proceeds of share issues 1,312 13,562 – – – – 14,874
Shares purchased for cancellation (320) – 320 – (3,522) – (3,522)
At 30 September 2025 11,985 76,195 1,788 7,483 40,379 576 138,406
               
Year ended 31 March 2026      
At 1 April 2025 10,993 62,633 1,468 4,939 47,177 868 128,078
Return after tax – – – 5,454 (7,725) 735 (1,536)
Dividends paid – – – – (6,480) (980) (7,460)
Net proceeds of share issues 2,200 22,913 – – – – 25,113
Shares purchased for cancellation (585) – 585 – (6,398) – (6,398)
At 31 March 2026 12,608 85,546 2,053 10,393 26,574 623 137,797

* On 2 July 2026, following shareholder approval and confirmation by the High Court, the Company’s share premium account was cancelled and £94.3 million was transferred to the capital reserve.

Condensed statement of cash flows

For the six months ended 30 September 2026

  Unaudited six months ended Unaudited six months ended Audited year ended
  30 September 2026 30 September 2025 31 March 2026
  £000 £000 £000
Cash flows from operating activities      
Return before tax 5,119 2,121 (1,536)
Adjustments for:      
(Gain)/loss on disposal of investments (4,881) 2 531
Movements in fair value of investments (861) (2,491) 61
(Increase)/decrease in debtors (20) 2,511 (25)
Decrease in creditors (40) (358) (336)
Net cash (outflow)/inflow from operating activities (683) 1,785 (1,305)
Cash flows from investing activities      
Purchase of investments (7,361) (5,473) (15,887)
Proceeds on disposal of investments 13,381 471 7,191
Net cash inflow/(outflow) from investing activities 6,020 (5,002) (8,696)
Cash flows from financing activities      
Issue of ordinary shares 10,387 15,409 25,963
Share issue expenses (346) (535) (850)
Purchase of ordinary shares for cancellation (1,853) (3,522) (6,398)
Costs of share premium cancellation (36) – –
Equity dividends paid (3,473) (3,145) (7,460)
Net cash inflow from financing activities 4,679 8,207 11,255
Net increase in cash and cash equivalents 10,016 4,990 1,254
Cash and cash equivalents at beginning of period 39,316 38,062 38,062
Cash and cash equivalents at end of period 49,332 43,052 39,316

Other matters

The Financial Statements are prepared in accordance with accounting policies consistent with Financial Reporting Standard 102 (“FRS 102”), Financial Reporting Standard 104 (“FRS 104”) – Interim Financial Reporting, with the Companies Act 2006 and the Statement of Recommended Practice, ‘Financial Statements of Investment Trust Companies and Venture Capital Trusts’ (“the SORP”) (updated in December 2025) issued by the Association of Investment Companies (“AIC”). These condensed financial statements comply with FRS 104, applying the recognition and measurement principles of FRS 102. The Financial Statements have been prepared on a going concern basis.

The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The most critical estimates and judgements relate to the determination of carrying value of investments at fair value through profit or loss (“FVTPL”) in accordance with FRS 102 sections 11 and 12. The Company values investments by following the International Private Equity and Venture Capital Valuation (“IPEV”) Guidelines as updated in 2025 and further detail on the valuation techniques used is outlined in the Annual Report and Financial Statements for the year ended 31 March 2026.

The accounting policies have been applied consistently throughout the period. Full details of principal accounting policies are disclosed in Note 1 on page 64 of the Annual Report and Financial Statements for the year ended 31 March 2026. The significant accounting estimates and judgements applied are consistent with those disclosed in the Annual Report for the year ended 31 March 2026.

Details of the agreement under which the investment management fee and performance-related fee are paid are given in the Directors’ Report on page 39 and in Note 3 on page 67 of the Annual Report and Financial Statements for the year ended 31 March 2026. The investment management fee for the six months ended 30 September 2026 has been calculated in accordance with these arrangements. As previously announced, revised fee arrangements under the investment management agreement became effective on 1 October 2026. Under the revised arrangements, the annual management fee has been reduced from 2.06% to 2.00% of net assets, with amendments also made to the basis of calculating management fees on cash balances (now 1.75% on balances over £30 million – previously 1.00% on balances over £20 million) and the frequency of fee calculations. In addition, no initial management fees will be charged by the Manager to new portfolio companies from that date.

The interim dividend of 1.7 pence per share for the year ending 31 March 2027 will be paid on 20 January 2027 to shareholders on the register on 18 December 2026.

The calculation of the return per share is based on the return after tax for the six months ended 30 September 2026 and on 268,465,244 (30 September 2025: 242,946,704) ordinary shares, being the weighted average number of shares in issue during the period.

The calculation of net asset value per share is based on the net assets at 30 September 2026 divided by the 266,589,293 (30 September 2025: 239,707,349) ordinary shares in issue at that date.

The information set out in this announcement does not constitute the Company’s statutory accounts within the terms of section 434 of the Companies Act 2006 for the periods ended 30 September 2026 and 30 September 2025 and is unaudited. The financial information for the year ended 31 March 2026 does not constitute statutory accounts within the terms of section 434 of the Companies Act 2006 and is derived from the statutory accounts for that financial year, which have been delivered to the Registrar of Companies. The Auditor reported on those accounts; their report was unqualified and did not contain a statement under s498(2) or (3) of the Companies Act 2006.

The Half-Yearly Financial Report is being sent to shareholders and copies will be made available to the public at the registered office of the Company, the National Storage Mechanism, and also electronically at www.mercia.co.uk/vcts.

20 November 2026

Northern Venture Trust PLC
Half-Yearly Financial Report for the six months ended 30 September 2026

Northern Venture Trust PLC is a Venture Capital Trust (VCT) advised by Mercia Fund Management Limited (the Investment Adviser). The trust was one of the first VCTs launched on the London Stock Exchange in 1995. It invests mainly in unquoted venture capital holdings and aims to provide long-term tax-free returns to shareholders through a combination of dividend yield and capital growth.

Financial summary

  Unaudited six months ended
30 September
2026
Unaudited six months ended
30 September
2025
Audited year
ended
31 March
2026
Net assets £151.7m £131.7m £138.2m
Net asset value per share 58.7p 60.7p 57.8p
Return per share      
Revenue 0.1p 0.1p 0.2p
Capital 2.0p 0.7p (0.8)p
Total 2.1p 0.8p (0.6)p
Dividend per share declared in respect of the period 1.5p 1.6p 3.1p
Cumulative return to shareholders since launch      
Net asset value per share 58.7p 60.7p 57.8p
Dividends paid per share* 199.9p 196.8p 198.4p
Net asset value plus dividends paid per share 258.6p 257.5p 256.2p
Mid-market share price at end of period 56.0p 56.5p 57.0p
Share price discount to net asset value 4.5% 6.9% 1.4%
Tax-free dividend yield
(based on net asset value per share)**
4.9% 5.2% 5.0%

* Excluding interim dividend not yet paid.

** The dividend yield is calculated by dividing the dividends declared in the 12-month period ended on each reference date by the net asset value per share at the start of that period.

Half-yearly financial report

It is my pleasure to present our Half-Yearly Financial Report. UK economic conditions from April to September remained challenging: the prolonged conflict in the Middle East pushed energy prices sharply higher, inflation rose to 3.5% in September, and gilt yields reached their highest level since 2007 amid concern over the public finances. Against this backdrop, the Company had a strong period for realisations and maintained its long-term strategy of investing in promising early-stage businesses, supporting its existing portfolio companies, and generating cash from realisations.

Venture capital investment activity and portfolio update
The value of the portfolio increased by £6.2 million over the 31 March 2026 holding value, comprising unrealised gains of £1.1 million and realised gains of £5.1 million. Gains on the stronger performers more than offset reductions elsewhere. Pure Pet Food increased in value by £2.7 million (including the partial realisation), Risk Ledger by £0.6 million and Semble by £0.6 million, while the largest reductions were in Scalpel and Axis Spine Technologies.

In the reporting period we sold our remaining holding in The Beauty Tech Group for £8.0 million. Together with the £2.5 million realised at its IPO on the London Stock Exchange in October 2025, the investment has delivered a 7.4x return on our original cost. We first invested in 2018.

In July 2026 we sold Send Technology Solutions for initial proceeds of £3.3 million, a 1.7x return on cost. We sold our holding in Buoyant Upholstery for an initial £1.3 million, a lifetime return of 2.5x. We also realised part of our holding in Pure Pet Food for £1.4 million, 5.5x the cost of the shares sold, and sold our remaining AIM-quoted holdings in RTC Group, CelLBxHealth and Velocity Composites for total proceeds of £0.4 million. In aggregate, realisations in the period were £5.1 million above the total 31 March 2026 holding values.

During the period, we made five new investments totalling £4.7 million: Flok Health (£1.0 million), a digital healthcare company providing AI-enabled physiotherapy services; Fifth Dimension AI (£1.0 million), a software company providing decision-intelligence tools for the real estate and real-assets sector; PlannerPal (£1.0 million), a provider of financial adviser workflow and compliance software; Equals (£0.9 million), a music-focused social networking and engagement platform; and Givestar (£0.8 million), a digital fundraising and charitable giving platform. We also deployed £2.6 million into seven existing portfolio companies.

Since the period end we have made a second tranche investment in Givestar of £1.5 million and an investment of £1.5 million in Bureau, a provider of office booths and meeting pods.

Results and dividend
The total return per share before dividends for the six months ended 30 September 2026 was 2.1 pence (2025: 0.8 pence), equivalent to 3.6% of the audited net asset value (NAV) per share of 57.8 pence at 31 March 2026. After deducting the final dividend for the year to 31 March 2026 of 1.5 pence, paid in September 2026, and taking account of the accretive effect of share issues above NAV and buy-backs below it, the unaudited NAV per share at 30 September 2026 was 58.7 pence.

In 2018 we introduced a target dividend yield of 5% of opening NAV, and have exceeded it every year since. Consistent with that target, the Board has declared an interim dividend of 1.5 pence per share in respect of the year ending 31 March 2027, to be paid on 20 January 2027 to shareholders on the register on 18 December 2026.

We continue to operate our dividend investment scheme, which enables shareholders to invest their dividends in new ordinary shares free of dealing costs and with the benefit of the tax reliefs available on new VCT share subscriptions. In September 2026, the Company issued 890,347 new shares under the scheme in respect of the final dividend. Details of the scheme are in the dividend section of our website at www.mercia.co.uk/vcts/nvt/.

Share issues and buy-backs
Under the extended 2025/26 share offer, the Company issued 22,761,845 shares on 2 April 2026 for gross proceeds of £14.1 million.

On 30 September 2026, in conjunction with the other Northern VCTs, we launched an offer to raise up to £10 million. The offer closes on 31 March 2027, or earlier if fully subscribed, and existing shareholders of any Northern VCTs receive a 0.5% discount on offer costs. Full details are on the Company’s website at mercia.co.uk/vcts.

We have maintained our policy of buying back the Company’s shares in the market when necessary to maintain liquidity, at a 5% discount to NAV. During the period the Company purchased 4,074,145 shares for cancellation at an average price of 55.2 pence, representing 1.7% of the opening share capital.

During the period the Company cancelled its share premium account, transferring £61.3 million to the capital reserve and increasing the reserves available for distribution.

Management fee
With effect from 1 October 2026, the Board has agreed revised fee arrangements with Mercia. The annual management fee has reduced from 2.06% to 2.00% of net assets, while the fee on cash balances has been restructured to reflect the level of cash held for future investment. Mercia will also no longer charge initial management fees to new portfolio companies. The Board believes this will benefit shareholders by making the Company a more attractive investor to high-quality, early-stage businesses, improving our access to the best opportunities and ensuring more of the capital we invest goes directly into growing those businesses. Further details are set out at the end of this announcement.

VCT legislation and qualifying status
The Company has continued to meet the stringent and complex qualifying conditions laid down by HM Revenue & Customs for maintaining its approval as a VCT. The Investment Adviser monitors the position closely and reports regularly to the Board. Philip Hare & Associates LLP has continued to act as independent adviser to the Company on VCT taxation matters.

As reported in the Annual Report, with effect from 6 April 2026, the Government increased the annual and lifetime investment limits for VCT-qualifying companies and cut income tax relief on new VCT subscriptions from 30% to 20%. The impact on investor appetite for VCTs remains uncertain.

Cash and liquidity
Cash balances at 30 September 2026 were £50.9 million (31 March 2026: £36.5 million), higher than usual following the April allotment and the realisations in the period. The Directors consider it important that the Company holds adequate cash to support the existing portfolio and to seize attractive investment opportunities. The Board will be mindful of the fundraising environment for VCTs as the implications of the new tax regime become apparent, but expects in the medium term to carry a significantly lower proportion of its resources as cash once it has better insight into the consequences of the tax changes for the VCT sector as a whole.

Outlook
Despite ongoing geopolitical and economic uncertainties, the realisations achieved in the period show that the portfolio can deliver value for the shareholders through the cycle. The Company will continue to invest selectively and to realise investments where the price is right. We believe the Company is well placed to continue to create shareholder value in the years ahead.

The Board thanks shareholders for their continuing support.

On behalf of the Board

Deborah Hudson
Chair

Statement of the Directors’ responsibilities

Responsibility statement
In accordance with Disclosure and Transparency Rule (DTR) 4.2.10, Deborah Hudson (Chair), Brigid Sutcliffe (Chair of the Audit & Risk Committee) and John Milad, being the Directors of the Company, confirm that to the best of their knowledge:

(a) the condensed set of financial statements, which has been prepared in accordance with Financial Reporting Standard 104 “Interim Financial Reporting”, gives a true and fair view of the assets, liabilities, financial position and profit of the Company as required by DTR 4.2.10;

(b) the Half-Yearly Financial Report includes a fair review of the information required by DTR 4.2.7, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;

(c) a description of the principal risks and uncertainties facing the Company for the remaining six months of the financial year is set out under the summary of principal risks and uncertainties below, in accordance with DTR 4.2.7; and

(d) other than the change in the management fee referred to in the Chair’s statement, there were no related party transactions in the first six months of the current financial year that are required to be disclosed, in accordance with DTR 4.2.8.

Principal risks and uncertainties
In accordance with DTR 4.2.7, the Board confirms that the principal risks and uncertainties facing the Company have not materially changed from those identified in the Annual Report and Financial Statements for the year ended 31 March 2026 (“the Annual Report”). The Board considers that the present processes for mitigating those risks remain appropriate. Following the realisation of all the Company’s quoted investments, the Board has removed stock market risk from the principal risks.

The principal risks faced by the Company are:

  • Artificial intelligence and advanced technology risk
  • Availability of qualifying investments risk
  • Economic and geopolitical risk
  • Financial risk
  • Investment and liquidity risk
  • Legislative and regulatory risk
  • Operational risk
  • Performance of the Investment Adviser risk
  • VCT qualifying status risk

A detailed explanation of the principal risks facing the Company can be found in the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 28 to 30, as well as in Note 18 on Financial Instruments on pages 78 to 80 of that report. Copies can be viewed or downloaded from the Company’s website: www.mercia.co.uk/vcts.

Environmental, Social and Governance considerations
The Company is committed to conducting its affairs responsibly and considers environmental, social and governance (ESG) issues as part of its operations. More details of the Company’s considerations can be found in the Responsible Investment section in the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 31 to 33.

Going concern
The Board has assessed the Company’s operation as a going concern. The Company’s business activities, together with the factors likely to affect its future development, performance and position are set out earlier in the Half-Yearly Financial Report. The Directors have satisfied themselves that the Company’s cash position is adequate to enable the Company to continue as a going concern under downside scenarios. The portfolio remains well funded and the Investment Adviser’s investment team are ensuring that management teams undertake adequate cost control and cash flow planning. The major cash outflows of the Company (namely investments, share buy-backs and dividends) are within the Company’s control. The Board’s assessment of liquidity risk and details of the Company’s policies for managing its capital and financial risks are shown in Note 18 of the Annual Report and Financial Statements for the year ended 31 March 2026 on pages 78 to 80. Accordingly, the Directors continue to adopt the going concern basis of accounting in preparing the Half-Yearly Financial Report.

Cautionary statement
This report may contain forward-looking statements with regard to the financial condition and results of the Company, which are made in the light of current economic and business circumstances. Nothing in this report should be construed as a profit forecast.

For and on behalf of the Board:

Deborah Hudson
Chair
20 November 2026

Investment portfolio
As at 30 September 2026 (unaudited)

  Description Cost
£000
Valuation
£000
% of net assets
by value
Fifteen largest venture capital investments        
Pure Pet Food Production of organic pet food 1,416 8,827 5.8
Risk Ledger Cyber security focused on supply chain risk 2,787 4,766 3.1
Semble Practice management software for healthcare clinics 2,961 4,526 3.0
Pimberly Product information management software 2,060 3,479 2.3
Broker Insights Platform connecting insurers and brokers 3,231 3,231 2.1
Biological Preparations Group Environmental biotechnology products 2,366 3,192 2.1
Tutora (t/a Tutorful) Platform for parents/students to engage tutors 3,305 2,941 1.9
Rockar E-commerce and fulfilment platform for new car sales 1,877 2,726 1.8
Forensic Analytics Call data communications analytics software 2,717 2,717 1.8
VoxPopMe Video-based consumer analysis platform 1,947 2,688 1.8
Ridge Pharma Sale of pharmaceuticals (branded, generics, specials) 1,497 2,589 1.7
Turbine Simulated Cell Technologies Simulation of cell reaction to disease treatment 2,372 2,538 1.7
Administrate SaaS training management and LMS platform 3,444 2,508 1.7
LMC Software Social care management software for care homes 1,950 2,296 1.5
Thanks Ben Employee benefits orchestration platform 2,280 2,280 1.5
Fifteen largest venture capital investments   36,210 51,304 33.8
Other venture capital investments   57,242 48,565 32.0
Total venture capital investments   93,452 99,869 65.8
Net current assets     51,803 34.2
Net assets     151,672 100.0

Extracts from the unaudited half-yearly financial statements for the six months ended 30 September 2026 are set out below

Condensed income statement

For the six months ended 30 September 2026

  Unaudited six months ended Unaudited six months ended Audited year ended
  30 September 2026 30 September 2025 31 March 2026
  Revenue Capital Total Revenue Capital Total Revenue Capital Total
  £000 £000 £000 £000 £000 £000 £000 £000 £000
Gain/(loss) on disposal of investments – 5,085 5,085 – (2) (2) – (197) (197)
Movements in fair value of investments – 1,086 1,086 – 2,413 2,413 – 87 87
                   
  – 6,171 6,171 – 2,411 2,411 – (110) (110)
                   
Dividend and interest income 1,025 – 1,025 933 – 933 1,803 – 1,803
Investment management fee (334) (1,001) (1,335) (305) (915) (1,220) (629) (1,888) (2,517)
Other expenses (257) – (257) (289) – (289) (563) – (563)
                   
Return before tax 434 5,170 5,604 339 1,496 1,835 611 (1,998) (1,387)
Tax on return (104) 104 – (50) 50 – (118) 118 –
                   
Return after tax 330 5,274 5,604 289 1,546 1,835 493 (1,880) (1,387)
                   
Return per share 0.1p 2.0p 2.1p 0.1p 0.7p 0.8p 0.2p (0.8)p (0.6)p

Condensed balance sheet

As at 30 September 2026

  Unaudited 30 September
2026
Unaudited 30 September
2025
Audited 31 March
2026
  £000 £000 £000
Fixed assets      
Investments 99,869 100,825 101,676
       
Current assets      
Debtors 1,029 118 197
Cash and cash equivalents 50,924 30,949 36,499
  51,953 31,067 36,696
       
Creditors (amounts falling due within one year) (150) (188) (208)
       
Net current assets 51,803 30,879 36,488
       
Net assets 151,672 131,704 138,164
       
Capital and reserves      
Called-up equity share capital 64,639 54,232 59,745
Share premium 311 44,073 53,443
Capital redemption reserve 11,870 9,806 10,851
Revaluation reserve 6,418 9,244 11,279
Capital reserve 67,671 13,601 1,894
Revenue reserve 763 748 952
Total equity shareholders’ funds 151,672 131,704 138,164
       
Net asset value per share 58.7p 60.7p 57.8p

Condensed statement of changes in equity

       
  Called-up share capital Share premium Capital redemption reserve Revaluation reserve Capital reserve Revenue reserve Total
  £000 £000 £000 £000 £000 £000 £000
Six months ended 30 September 2026 (unaudited)              
               
At 1 April 2026 59,745 53,443 10,851 11,279 1,894 952 138,164
Return after tax – – – (4,861) 10,135 330 5,604
Dividends paid – – – – (3,371) (519) (3,890)
Net proceeds of share issues 5,913 8,178 – – – – 14,091
Shares purchased for cancellation (1,019) – 1,019 – (2,261) – (2,261)
Cancellation of share premium account – (61,310) – – 61,310 – –
Costs of share premium cancellation – – – – (36) – (36)
At 30 September 2026 64,639 311 11,870 6,418 67,671 763 151,672
               
Six months ended 30 September 2025 (unaudited)      
At 1 April 2025 49,302 35,348 8,476 6,779 20,451 895 121,251
Return after tax – – – 2,465 (919) 289 1,835
Dividends paid – – – – (2,835) (436) (3,271)
Net proceeds of share issues 6,260 8,725 – – – – 14,985
Shares purchased for cancellation (1,330) – 1,330 – (3,096) – (3,096)
At 30 September 2025 54,232 44,073 9,806 9,244 13,601 748 131,704
               
Year ended 31 March 2026      
At 1 April 2025 49,302 35,348 8,476 6,779 20,451 895 121,251
Return after tax – – – 4,500 (6,380) 493 (1,387)
Dividends paid – – – – (6,679) (436) (7,115)
Net proceeds of share issues 12,818 18,095 – – – – 30,913
Shares purchased for cancellation (2,375) – 2,375 – (5,498) – (5,498)
At 31 March 2026 59,745 53,443 10,851 11,279 1,894 952 138,164

Condensed statement of cash flows

For the six months ended 30 September 2026

  Unaudited six months ended Unaudited six months ended Audited year ended
  30 September 2026 30 September 2025 31 March 2026
  £000 £000 £000
Cash flows from operating activities      
Return before tax 5,604 1,835 (1,387)
Adjustments for:      
(Gain)/loss on disposal of investments (5,085) 2 197
Movements in fair value of investments (1,086) (2,413) (87)
(Increase)/decrease in debtors (34) 2,777 (24)
Decrease in creditors (58) (432) (412)
Net cash (outflow)/inflow from operating activities (659) 1,769 (1,713)
Cash flows from investing activities      
Purchase of investments (7,329) (5,393) (15,601)
Proceeds on disposal of investments 14,509 516 10,076
Net cash inflow/(outflow) from investing activities 7,180 (4,877) (5,525)
Cash flows from financing activities      
Issue of ordinary shares 14,609 15,474 31,943
Share issue expenses (518) (489) (1,032)
Purchase of ordinary shares for cancellation (2,261) (3,096) (5,498)
Costs of share premium cancellation (36) – –
Equity dividends paid (3,890) (3,271) (7,115)
Net cash inflow from financing activities 7,904 8,618 18,298
Net increase in cash and cash equivalents 14,425 5,510 11,060
Cash and cash equivalents at beginning of period 36,499 25,439 25,439
Cash and cash equivalents at end of period 50,924 30,949 36,499

Other matters

The Financial Statements are prepared in accordance with accounting policies consistent with Financial Reporting Standard 102 (“FRS 102”), Financial Reporting Standard 104 (“FRS 104”) – Interim Financial Reporting, with the Companies Act 2006 and the Statement of Recommended Practice, ‘Financial Statements of Investment Trust Companies and Venture Capital Trusts’ (“the SORP”) (updated in December 2025) issued by the Association of Investment Companies (“AIC”). These condensed financial statements comply with FRS 104, applying the recognition and measurement principles of FRS 102. The Financial Statements have been prepared on a going concern basis.

The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The most critical estimates and judgements relate to the determination of carrying value of investments at fair value through profit or loss (“FVTPL”) in accordance with FRS 102 sections 11 and 12. The Company values investments by following the International Private Equity and Venture Capital Valuation (“IPEV”) Guidelines as updated in 2025 and further detail on the valuation techniques used is outlined in the Annual Report and Financial Statements for the year ended 31 March 2026.

The accounting policies have been applied consistently throughout the period. Full details of principal accounting policies are disclosed in Note 1 on page 65 of the Annual Report and Financial Statements for the year ended 31 March 2026. The significant accounting estimates and judgements applied are consistent with those disclosed in the Annual Report for the year ended 31 March 2026.

Details of the agreement under which the investment management fee and performance-related fee are paid are given in the Directors’ Report on page 39 and in Note 3 on page 68 of the Annual Report and Financial Statements for the year ended 31 March 2026. The investment management fee for the six months ended 30 September 2026 has been calculated in accordance with these arrangements. As previously announced, revised fee arrangements under the investment advisory agreement became effective on 1 October 2026. Under the revised arrangements, the annual management fee has been reduced from 2.06% to 2.00% of net assets, with amendments also made to the basis of calculating management fees on cash balances (now 1.75% on balances over £30 million – previously 1.00% on balances over £20 million) and the frequency of fee calculations. In addition, no initial management fees will be charged to new portfolio companies from that date.

The interim dividend of 1.5 pence per share for the year ending 31 March 2027 will be paid on 20 January 2027 to shareholders on the register on 18 December 2026.

The calculation of the return per share is based on the return after tax for the six months ended 30 September 2026 and on 260,666,935 (30 September 2025: 219,187,995) ordinary shares, being the weighted average number of shares in issue during the period.

The calculation of net asset value per share is based on the net assets at 30 September 2026 divided by the 258,557,032 (30 September 2025: 216,925,150) ordinary shares in issue at that date.

The information set out in this announcement does not constitute the Company’s statutory accounts within the terms of section 434 of the Companies Act 2006 for the periods ended 30 September 2026 and 30 September 2025 and is unaudited. The financial information for the year ended 31 March 2026 does not constitute statutory accounts within the terms of section 434 of the Companies Act 2006 and is derived from the statutory accounts for that financial year, which have been delivered to the Registrar of Companies. The Auditor reported on those accounts; their report was unqualified and did not contain a statement under s498(2) or (3) of the Companies Act 2006.

The Half-Yearly Financial Report is being sent to shareholders and copies will be made available to the public at the registered office of the Company, the National Storage Mechanism and also electronically at www.mercia.co.uk/vcts.

LIMASSOL, Cyprus, Nov. 20, 2026 (GLOBE NEWSWIRE) — Robin Energy Ltd. (NASDAQ: RBNE) (“Robin Energy” or the “Company”), an international ship-owning company providing energy transportation services globally, announced today that its board of directors has determined to effect a one-for-seventy-five (1-for-75) reverse stock split of the Company’s common shares, par value $0.001 per share.

The reverse stock split will take effect at 11:59 p.m. Eastern Time on November 23, 2026, and the Company’s common shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) as of the opening of trading on November 24, 2026, under the existing ticker symbol “RBNE”. The CUSIP number of Y73118138 will be assigned to the Company’s common shares when the reverse stock split becomes effective.

When the reverse stock split becomes effective, every seventy-five (75) of the Company’s issued and outstanding common shares will be combined into one issued and outstanding common share, without any change to the par value per share or any shareholder’s ownership percentage of the Company’s common shares, subject to the effects of any rounding. This will reduce the number of currently outstanding common shares from approximately 81.9 million shares to approximately 1.1 million shares. Immediately following the effective time of the reverse stock split, the Company’s common shares will have the same voting rights and will be identical in all other aspects to the common shares prior to effectiveness of the reverse stock split.

No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise receive a fraction of a common share of the Company as a result of the reverse stock split will receive a cash payment in lieu thereof at a price equal to that fraction of a share to which the stockholder would otherwise be entitled, multiplied by the closing price of the Company’s common shares on Nasdaq on November 23, 2026 (as adjusted for the reverse split).

Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after November 24, 2026. Such beneficial holders may contact their bank, broker, or nominee for more information.

The reverse stock split ratio approved by the board of directors is within the range of ratios for a reverse stock split authorized by the stockholders of the Company.

About Robin Energy Ltd.

Robin Energy is an international ship-owning company providing energy transportation services globally. Upon completion of our recently announced acquisition, the Company’s fleet will comprise three LPG Carriers that carry petrochemical gases worldwide.

For more information, please visit the Company’s website at www.robinenergy.com. Information on our website does not constitute a part of this press release.

Cautionary Statement Regarding Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including those related to our reverse stock split. We are including this cautionary statement in connection with this safe harbor legislation. The words “believe”, “anticipate”, “intend”, “estimate”, “forecast”, “project”, “plan”, “potential”, “will”, “may”, “should”, “expect”, “pending” and similar expressions identify forward-looking statements.

Forward-looking statements are subject to risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future and/or are beyond our control or precise estimate. Such risks, uncertainties and other factors include, but are not limited to, uncertainties related to market conditions, as well as those factors discussed under “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2025 and our other filings with the SEC, which can be obtained free of charge on the SEC’s website at http://www.sec.gov. Except to the extent required by applicable law, we disclaim any intention or obligation to update publicly or revise any forward‐looking statements, whether as a result of new information, future events or otherwise.

CONTACT DETAILS

For further information please contact:

Investor Relations
Robin Energy Ltd.
Email: ir@robinenergy.com

  • Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech’s CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against cancers expressing antigens of interest while overcoming inhibitory signals that constrain anti-tumor immunity.
  • CAPTN-3 antibodies combine an NKG2A arm that blocks an inhibitory immune checkpoint with a capped CD3 arm designed to penetrate into solid cancers and activate T cells only within the tumor microenvironment, distinguishing the platform from conventional T-cell engagers that activate T cells before reaching their target.
  • IM1240, targeting 5T4, an oncofetal antigen expressed on a wide range of cancers, demonstrated potent anti-tumor activity in patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy, including a muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab.
  • NKG2A engagement is a key contributor to tumor killing, as demonstrated in studies using IM1240 and matched antibody variants in patient-derived cancer specimens, supporting the platform’s strategy of targeting both innate and adaptive immune responses.
  • In non-human primates, CD3 capping markedly reduced cytokine release and extended systemic exposure compared with a non-capped variant, with an approximately 8-fold longer half-life and 16-fold greater exposure, further supporting the potential of IM1240 to combine potent anti-tumor activity with a broad therapeutic window.

REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.

CAPTN-3 is Purple Biotech’s platform of capped tri-specific antibodies. Each antibody combines three arms in a single molecule: a targeting arm that binds a cancer-associated antigen and can be exchanged to address different cancers; a CD3 arm that engages T cells; and an NKG2A arm that engages NK cells and blocks an inhibitory immune checkpoint. The CD3 arm is capped: it is designed to remain inactive in circulation and to be uncapped by proteases in the tumor microenvironment, confining T-cell activation to the cancer and, based on preclinical data, expanding the therapeutic window compared with non-capped T-cell engagers. IM1240, the platform’s lead candidate, targets 5T4.

The findings were presented in a plenary oral session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute.

“One of the central challenges in cancer immunotherapy is that the presence of cytotoxic immune cells within a tumor does not necessarily translate into effective tumor control. A major blind spot when introducing novel drugs is the assumption that cancer is stagnant in the face of frontline therapies,” said Dr. Amir Horowitz. “Our research on the HLA-E/NKG2A pathway has shown how tumors can exploit inhibitory signals to restrain otherwise capable natural killer (NK) cells and T cells. The IM1240 findings provide compelling preclinical evidence for a therapeutic strategy that combines tumor-directed T-cell engagement with relief of NKG2A-mediated immune suppression. The activity observed in treatment-resistant human tumor models is particularly encouraging and warrants further investigation.”

“These findings address two key challenges in developing T-cell engagers for solid cancers: immune resistance and systemic immune activation,” said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. “Our objective is not simply to recruit more immune cells to cancers, but to enable a more effective anti-tumor response by combining targeted immune engagement with the ability to counteract inhibitory mechanisms within the tumor microenvironment. The contribution of the NKG2A arm in immunotherapy-resistant human cancers, together with the favorable safety and pharmacokinetic profile of our CD3 capping technology, strengthens the scientific foundation as we advance IM1240 toward the clinic.”

Presentation Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety

Abstract: ENA26-0137
Session: Plenary Session 7 – Proffered Papers: Novel Agents and Targets
Date and Time: Friday, November 20, 2026, 15:24 CET

Addressing immune resistance beyond T-cell recruitment

While T-cell engagers are designed to bring cytotoxic T cells into contact with cancer cells, their activity may remain limited by immunosuppressive mechanisms within the tumor microenvironment. One such mechanism is the HLA-E/NKG2A immune checkpoint: HLA-E, expressed by tumor cells, binds the inhibitory NKG2A receptor on NK cells and subsets of cytotoxic T cells, suppressing their anti-tumor function.

Dr. Horowitz’s work has helped establish the HLA-E/NKG2A pathway as an important regulator of anti-tumor immunity. Recent research from his laboratory, posted as a preprint, found that bladder cancers unresponsive to BCG immunotherapy can retain populations of potentially cytotoxic immune cells while exhibiting increased HLA-E/NKG2A inhibitory interactions. Experimental blockade of NKG2A restored immune-cell function in patient-derived tumor co-cultures, highlighting a potentially actionable mechanism of immune resistance.

These observations reinforce the scientific rationale underlying CAPTN-3: effective anti-tumor immunity may require not only bringing immune cells to cancer cells but also overcoming the inhibitory signals that prevent those immune cells from functioning effectively.

IM1240 integrates three complementary functions within a single antibody: recognition of the tumor-associated antigen 5T4, capped CD3-mediated T-cell redirection, and NKG2A engagement designed to block inhibitory signaling affecting NK cells and cytotoxic T cells. 5T4 is expressed in a variety of solid cancers and is associated with advanced disease and poor clinical outcomes.

NKG2A engagement enhances IM1240’s anti-tumor activity

Data presented at ENA 2026, building on data first presented at the EACR 2026 Annual Congress in June, demonstrated that IM1240 induced anti-tumor activity in patient-derived tumor specimens collected following prior immunotherapy-containing treatment regimens: six head and neck squamous cell carcinoma metastatic lymph node samples, one muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab, and one non-small cell lung cancer (NSCLC) tumor resistant to neoadjuvant chemotherapy plus PD-1 blockade. In the dissociated head and neck and bladder specimens, tumor-cell killing required functional CD3 and NKG2A arms; in cancer cell lines, activity depended on 5T4 expression.

In a patient-derived NSCLC explant obtained following chemotherapy and PD-1 inhibitor treatment, IM1240 demonstrated substantially greater anti-tumor activity, achieving an in situ pathologic response score of 94 on a 0–100 scale, compared with 49 for an otherwise comparable antibody with an inactivated NKG2A-binding arm. Similarly, preventing CD3 activation with a non-cleavable cap reduced the response score to 38, highlighting the critical contribution of both functional components to IM1240’s anti-tumor activity.

Spatial imaging of treated NSCLC explants revealed differences in immune-cell distribution and cell-cell interactions between IM1240 and the NKG2A-inactive comparator, suggesting that NKG2A engagement may influence not only direct tumor-cell killing but also the broader immune organization of the tumor microenvironment.

Collectively, these findings provide functional evidence that incorporating NKG2A targeting into a capped T-cell engager can enhance anti-tumor activity beyond CD3-mediated T-cell redirection alone.

CD3 capping supports a favorable safety and pharmacokinetic profile

In addition to its multi-arm immune mechanism, IM1240 incorporates Purple Biotech’s proprietary protease-cleavable CD3 capping technology, designed to restrict full T-cell engagement until the antibody encounters proteolytic conditions associated with the tumor microenvironment.

The ENA presentation also shows that protease-mediated cap removal restores CD3 binding and immune-cell-mediated tumor killing, while a non-cleavable control remains functionally restricted.

Preclinical non-human primate studies further demonstrated that this capping strategy substantially reduced systemic cytokine responses compared with a non-capped antibody, even at higher doses, and prolonged systemic exposure through reduced clearance. As previously reported, IM1240 induced minimal IL-6 and TNF-α at 10 mg/kg, whereas the non-capped variant, IM1222, induced robust cytokine release at just 0.03 mg/kg. IM1240 also showed an approximately 8-fold longer half-life and 16-fold greater systemic exposure.

Together, these findings support a design in which IM1240 circulates with its CD3 arm capped and is activated within the tumor microenvironment, potentially allowing sustained exposure while limiting premature peripheral T-cell activation.

About CAPTN-3

CAPTN-3 is Purple Biotech’s proprietary platform of capped tri-specific antibodies designed to combine tumor-antigen recognition, T-cell engagement, and NKG2A-mediated immune checkpoint modulation. The platform integrates a protease-cleavable CD3 capping mechanism intended to limit systemic T-cell activation while enabling anti-tumor activity within the tumor microenvironment.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 – a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology is designed to confine immune activation to the tumor microenvironment and, based on preclinical data, to expand the therapeutic window compared to conventional T-cell engagers. The platform’s lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue”, “potential”, “designed to” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; our ability to raise additional capital on acceptable terms, or at all, to fund our research and development activities, including preclinical and clinical studies; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2025 as such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission (“SEC”), including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, https://www.sec.gov.

CONTACTS:

Company Contact:
IR@purple-biotech.com

Two studies test how AI agents negotiate freight rates under competition and how voice agents perform in Spanish; the Company also releases an open-source research toolkit for benchmarking negotiation agents and launches an AI Lab section on its redesigned website

HOUSTON, Nov. 20, 2026 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT, “Fr8Tech” or the “Company”), a technology-centric logistics company offering a diversified portfolio of AI software solutions designed to address key inefficiencies in the supply chain, today announced that its in-house AI Lab has published two research papers on the design of AI agents for freight negotiation, together with an open-source research toolkit for benchmarking negotiation agents. The papers are available as preprints on arXiv and in a new AI Lab section of the Company’s redesigned website.

The first paper informs the negotiation agents of Zayren, the Company’s AI-based pricing-prediction, carrier-matching and negotiation platform. The second paper examines the voice architecture the Company is building into its products. The AI Lab ran controlled experiments to measure how AI architectures behave in freight-specific conditions and used the results to inform the ongoing development of Fr8Tech’s products. The AI Lab section of the website details seven capability areas, from pricing and AI agents to computer vision and document intelligence, with components from these areas already running inside the Company’s products.

The first paper, “Before AI Agents Negotiate for Us” (arXiv:2611.15838), compares nine negotiation engines, from rule-based and optimization designs to reinforcement-learning policies, run simultaneously on both sides of a simulated freight brokering market, under balanced conditions and under shortages of carriers or shippers. Through the same protocol, nine open-weight large language models (LLMs), ranging from 1 billion to 72 billion parameters, were run on the Lab’s own hardware. In the end, the two strongest purpose-built engines outperformed the nine LLMs tested in 32 of 36 statistically corrected comparisons and never lost. The testing also exposed a failure: a reinforcement-learning engine that closed deals on 62% of trading days in a balanced market dropped to 16% when it had to compete for scarce demand. Catching failures like this in simulation, before an agent reaches a customer, is the purpose of the Lab’s testing. The Company believes these findings support its approach of building negotiation agents on purpose-built architectures tested under simulated market stress, rather than just on a general-purpose language model.

“Our AI Lab exists to ground our technology in evidence-based research, not on assumptions about what it can do,” said Javier Selgas, Chief Executive Officer of Freight Technologies. “Placing AI upstream of traditional transportation management means letting software negotiate, monitor, and execute. But before we hand those decisions to an agent, we want to know, with data, how it will behave when the market turns against it. Publishing this work openly is part of building that trust with our customers and with the market.”

The second paper, “Latency, Speech Recognition and Turn-Taking in Voice Agents for Spanish Phone Negotiation: An Externally Measured Comparison of Pipecat, LiveKit and GPT-Live” (arXiv:2611.19118), evaluates three voice-agent architectures tested across 231 recorded calls in Spanish, simulating freight negotiations with a scripted carrier. Two were cascaded pipelines, in which separate components transcribe the carrier’s speech, generate the reply and synthesize the voice; the third was a native speech-to-speech architecture that listens and speaks directly, without intermediate transcription. In the study, the speech-to-speech architecture misinterpreted less than 3% of spoken monetary amounts, compared with approximately 13% for the two pipelines, and it was the only one to not record an agreement that the carrier did not accept. These results inform the voice capabilities the Company is building into its products, from voice-driven negotiation to voice control of its software.

“We do not assume what an architecture can do; we build the test environment, run the experiment and let the result decide,” said Umberto León Domínguez, Director of Fr8Tech’s AI Lab. “In the negotiation study, no language model we tested won a single comparison against the strongest purpose-built engines. In the voice study, the difference between architectures was in how they listen, not in how fast they talk. Both answers came from measurement, not from assumptions, and both are shaping what we build.”

The research toolkit is available on GitHub under an Apache 2.0 license, so that researchers and logistics companies can benchmark their own negotiation agents under the same protocol.

To read the papers and learn more about the AI Lab, please visit fr8technologies.com/en/ai-lab

About Freight Technologies Inc.

Freight Technologies, Inc. (Nasdaq: FRGT) (“Fr8Tech”) is a technology company offering a diverse portfolio of platform solutions that are powered by AI and machine learning to optimize and automate the supply chain process. Focused on addressing the distinct challenges within the supply chain ecosystem, the Company’s portfolio of solutions includes the Fr8App platform for over-the-road (OTR) B2B cross-border shipping across the USMCA region; Fleet Rocket, a nimble, scalable and cost-effective Transportation Management System (TMS) for brokers, shippers, and other logistics operators; Fr8Radar, a GPS integration and shipment visibility module within Fleet Rocket that enables real-time tracking of in-transit freight across the U.S.-Mexico corridor; Zayren, an AI-based pricing-prediction, carrier-matching and negotiation platform for OTR freight shipments across North America; and DODA Smart, an AI-powered customs compliance platform to automatically monitor, verify and trace Digital Customs Documents (DODAs) for trade operators in Mexico. Each product is interconnected within a unified platform to connect carriers and shippers and improve matching and operational efficiency via technologies such as live pricing, real-time tracking, digitization of critical documentation, brokerage support, transportation management, fleet management, and committed capacity solutions. For more information, please visit fr8technologies.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Fr8Tech’s and its subsidiary Fr8App Inc.’s actual results may differ from their expectations, estimates, and projections and, consequently, readers should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. Forward-looking statements in this press release include statements regarding the capabilities the Company is developing for its products and the anticipated application of its AI Lab research, including potential future applications of that research.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Fr8Tech’s and Fr8App Inc.’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the inability to obtain or maintain the listing of Fr8Tech’s ordinary shares on Nasdaq; (2) changes in applicable laws or regulations, including laws and regulations governing artificial intelligence and data privacy; (3) the possibility that Fr8Tech or Fr8App Inc. may be adversely affected by other economic, business and/or competitive factors; (4) risks relating to the uncertainty of the projected financial information with respect to Fr8App Inc.; (5) risks related to the organic and inorganic growth of Fr8App Inc.’s business and the timing of expected business milestones; (6) risks related to the Company’s development and use of artificial intelligence, including inaccurate or unexpected outputs, the possibility that research results obtained in controlled or simulated settings may not be replicated in commercial use, market acceptance of AI-enabled products, and reliance on third-party AI models and providers, whose availability, pricing or terms may change; and (7) other risks and uncertainties identified, including those under “Risk Factors,” to be filed in Fr8Tech’s filings with the Securities and Exchange Commission.

Fr8Tech cautions that the foregoing list of factors is not exclusive. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Fr8Tech and Fr8App Inc. caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Fr8Tech and Fr8App Inc. do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

CONTACT: Fr8Tech Contact:

Jason Finkelstein
IGNITION Investor Relations
investors@fr8technologies.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.